Home›Stock Screener›Gujarat Themis Biosyn

Gujarat Themis Biosyn Share Price Today | Stock Price & Gujarat Themis Biosyn Share Screener

GUJTHEM Pharmaceuticals & Biotechnology
Live Share Price NSE
₹359.20
▼ -3.60 (-0.99%)
2026-11-19 00:00:00
Live Share Price BSE
₹358.20
▼ -3.40 (-0.94%)
2026-11-19 00:00:00

As of November 19, 2026, the live Gujarat Themis Biosyn share price (NSE: GUJTHEM) is ₹359.20 on NSE and ₹358.20 on BSE, down 0.99% from the previous close, with shares trading between ₹355.10 and ₹362.80 in today's trading session, and a 52-week range of ₹226.90–₹453.25. Track GUJTHEM market value to gauge the company's total market size. Use the Gujarat Themis Biosyn stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gujarat Themis Biosyn opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹45 and net income of ₹11, with EBITDA of ₹20, an operating margin of 44.0% and a profit margin of 24.4%.

Gujarat Themis Biosyn Market Cap ₹4,721.90 Cr.
GUJTHEM P/E Ratio (TTM) 220.80
Gujarat Themis Biosyn P/B Ratio 4.44
EPS (TTM) ₹4.28
Dividend Yield 0.19%
Debt to Equity 0.36
GUJTHEM 52 Week High ₹453.25
Gujarat Themis Biosyn 52 Week Low ₹226.90
Operating Margin 44.00%
Profit Margin 24.44%
GUJTHEM Revenue (TTM) ₹45.00
EBITDA ₹20.00
Net Income ₹11.00
Total Assets ₹503.00
Total Equity ₹288.00

Gujarat Themis Biosyn Share Price Chart

Track the current stock price of Gujarat Themis Biosyn with an interactive chart. Analyse GUJTHEM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gujarat Themis Biosyn stock quote in one place.

The quote of ₹359.20 sits between the 52-week low of ₹226.90 and the 52-week high of ₹453.25, and the latest session moved -0.99% from the previous close.

Gujarat Themis Biosyn Company Profile - Fundamental Screener

Screen Gujarat Themis Biosyn company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GUJTHEM shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE942C01045.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE942C01045

Gujarat Themis Biosyn Balance Sheet Screener

Screen GUJTHEM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹503, up from ₹301 in 2025.

Latest statistics put total assets at ₹503 and shareholder funds at ₹288, with a leverage ratio of 0.36.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 503 301 221 166 123 88 64 33 21 21
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 289 41 38 33 19 19 17 15 11 11

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 137 32 4 2 2 3 5 1 1 1
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 288 248 201 149 103 70 42 19 12 8
Share Capital 11 11 7 7 7 7 7 7 7 7
Reserves & Surplus 277 238 194 142 96 63 35 11 5 1

Gujarat Themis Biosyn Income Statement Screener - Profit & Revenue Analysis

Screen Gujarat Themis Biosyn income statement and profit fundamentals. Analyze GUJTHEM quarterly results. Gujarat Themis Biosyn reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹45 and net profit was ₹11, equal to earnings per unit of ₹1.00, at an operating margin of 44%.

In that period expenses were ₹25, interest cost ₹2 and tax ₹3. The next period listed, 2026-Jun, shows revenue of ₹44 and net profit of ₹11.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Jun 2025-Sept 2025-Dec

Revenue and Expenses

Revenue 45 44 54 36 43 44
Expenses 25 23 52 22 21 22

Operating Costs and Margins

EBITDA 20 21 2 14 22 22
Operating Profit % 44.00% 47.00% -4.00% 39.00% 49.00% 49.00%
Depreciation 4 4 5 2 3 4
Interest 2 2 8 0 0 1

Profit and Earnings

Profit Before Tax 14 15 -11 12 19 17
Tax 3 4 3 3 5 4
Net Profit 11 11 -14 9 14 13
EPS 1.00 1.02 -1.19 0.83 1.31 1.14

Gujarat Themis Biosyn Cash Flow Screener - Liquidity Fundamentals

Screen GUJTHEM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹49, and net cash flow was an outflow of ₹9.

Over the same period, investing activities used ₹172 and financing activities provided ₹115.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 49 91 64 40 40 11 1 1 6 3
Investing Activities -172 -112 -55 -20 -30 -2 -3 -6 -1 -3

Financing and Net Cash

Financing Activities 115 26 -9 -13 -14 -5 2 5 -4 0
Net Cash Flow -9 5 0 6 -4 3 0 0 1 0

Gujarat Themis Biosyn Shareholding Pattern Screener

See Gujarat Themis Biosyn shareholding pattern with promoter, FII, and DII holdings. Check Gujarat Themis Biosyn promoter holding and ownership changes for GUJTHEM on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 70.86%, foreign institutions 1.80%, domestic institutions 1.18% and the public 19.88%, spread across 26,886 shareholders.

The shareholder count was 26,886 in 2026-Mar, compared with 27,010 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Aug 2026-Sept 2025-Feb 2025-Mar 2025-Jun 2025-Sept

Promoter Holding

Promoter Holding 70.86% 70.86% 59.33% 59.33% 70.86% 70.86% 70.86% 70.86%

Institutional Investors

FII Holding 1.80% 1.77% 4.93% 3.80% 0.00% 1.91% 2.51% 2.95%
DII Holding 1.18% 1.18% 13.79% 12.65% 1.16% 1.17% 1.17% 1.17%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 19.88% 19.46% 16.43% 16.54% 19.75% 19.66% 19.31% 18.72%
Other Holding 6.28% 6.73% 5.52% 7.68% 8.22% 6.39% 6.14% 6.29%
Shareholder Count 26,886 27,010 26,899 28,781 30,695 30,673 28,945 28,319

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gujarat Themis Biosyn. Gujarat Themis Biosyn dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.67 per unit for 2026-March, a yield of 0.19%, compared with ₹0.67 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.67, ₹0.67 and ₹1.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.67 0.19%
2025-March ₹0.67 0.30%
2024-March ₹1.00 0.35%
2023-March ₹5.40 2.04%
2022-March ₹11.00 12.02%
2021-March ₹0.00 0.00%
2020-March ₹1.65 6.08%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Gujarat Themis Biosyn Stock Index Membership - Nifty & Sensex

See which indices include Gujarat Themis Biosyn stock. Check GUJTHEM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 2 indices, including BSE INDEX BSE HC.

Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE INDEX BSE HC
BSE INDEX SMLCAP

Gujarat Themis Biosyn Market Events Screener - Corporate Actions

Get Gujarat Themis Biosyn corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gujarat Themis Biosyn stock events that may affect GUJTHEM share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 14, 2026, with a record date of November 14, 2026.

It is followed by Annual General Meeting dated September 30, 2026 and Dividend dated September 23, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-14 2026-11-14 Quarterly Result Announcement NA 15.25%
2026-09-30 2026-09-30 Annual General Meeting NA -4.35%
2026-09-23 2026-09-23 Dividend ₹ 0.67 /share 11.63%
2026-08-22 2026-08-22 Extraordinary General Meeting NA 8.45%
2026-08-07 2026-08-07 Quarterly Result Announcement NA 2.69%
2026-05-25 2026-05-25 Quarterly Result Announcement NA 6.10%
2026-02-05 2026-02-05 Quarterly Result Announcement NA 6.98%
2025-11-10 2025-11-10 Quarterly Result Announcement NA -2.76%
2025-09-12 2025-09-12 Annual General Meeting NA 5.18%
2025-09-04 2025-09-05 Dividend ₹ 0.67 /share 14.14%
2025-08-01 2025-08-01 Quarterly Result Announcement NA 7.60%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 6.23%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -12.92%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -7.92%
2024-08-09 2024-08-09 Bonus 1:2 3.18%

Gujarat Themis Biosyn Competitors Screener - Peer Stocks Comparison

Screen GUJTHEM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 449,036 40.80 61,674 12.69% 11,565 60.77
Divis Laboratories 293,316 87.70 11,067 13.95% 2,568 65.94
Torrent Pharmaceuticals 175,376 84.70 13,886 20.34% 2,138 42.26
Laurus Labs 125,488 94.90 6,868 22.01% 890 55.82
Zydus Life Science 119,900 27.90 27,658 17.64% 5,026 55.22
Dr Reddys Laboratories 116,705 42.00 35,059 3.90% 4,158 73.09
Cipla 114,474 39.20 29,045 2.24% 3,870 62.07
Mankind Pharma 108,424 47.50 14,636 14.85% 1,938 62.66
Aurobindo Pharma 103,355 25.90 34,145 5.56% 3,503 60.69
Lupin 90,173 17.10 29,039 26.75% 5,356 44.73

Gujarat Themis Biosyn Company Announcements - News & Reports Screener

Screen GUJTHEM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 18, 2026.

The next most recent announcements are dated November 17, 2026 and November 17, 2026.

Date Update Actions
2026-11-18 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-17 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-17 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-16 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-15 Announcement under Regulation 30 (LODR)-Change in Management -
2026-11-15 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-11-15 Results: Financial Results For The Quarter And Half Year Ended 30.09.2026 -
2026-11-15 Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.11.2026 -
2026-11-04 Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - Additional Disclosures In Relation To The Preferential Issue. -
2026-11-02 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-02 Update on board meeting -
2026-10-27 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-27 Board Meeting Intimation for Consideration And Approval Of Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30.09.2026 -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-30 Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association -
2026-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹359.20, within a 52-week range of ₹226.90 to ₹453.25. The P/E ratio is 220.80 and the P/B ratio is 4.44, with earnings per unit of ₹4.28. Market capitalisation stands at ₹4,721.90 Cr and the dividend yield is 0.19%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 6 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.